GSK2110183 Size:Solid 2 mg Co-administration of 20(S)-protopanaxatriol (g-PPT) and

Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer

R112 also blocked leukotriene C4 production and all proinflammatory cytokines tested

CAS Number: 510-77-0

InChi: InChI=1S/C22H30N2O2S/c1-4-16(2)13-23-14-22(25)24-10-8-21-19(9-11-27-21)20(24)15-26-18-7-5-6-17(3)12-18/h5-7

GSK2110183 Size:Solid 2 mg Co-administration of 20(S)-protopanaxatriol (g-PPT) andAfuresertib F is an analogue of Afuresertib with one more flurorine atom compared to its parent drug Afuresertib. Afuresertib F is an ATK inhibitor. Afuresertib, also known as GSK 2110183 or GSK 2110183C, is an cancer drug candidate under clinical trial. Product information CAS Number: 1047634 63 8 Molecular Weight: 445. 31 Formula: C18H16Cl2F2N4OS Synonym: GSK 2110183 Chemical Name: N [(2S) 1 amino 3 (3,4 difluorophenyl)propan 2 yl] 5 chloro 4 (4